NRIX

Nurix Therapeutics (NRIX)

About Nurix Therapeutics (NRIX)

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Details

Daily high

$10.14

Daily low

$9.30

Price at open

$9.49

52 Week High

$29.56

52 Week Low

$8.18

Market cap

725.0M

Dividend yield

0.00%

Volume

1.4M

Avg. volume

826,704

P/E ratio

-3.39

Nurix Therapeutics News